Paul D'Angio
Director/Board Member bij NEXIMMUNE, INC.
Vermogen: 6 244 $ op 31-03-2024
Actieve functies van Paul D'Angio
| Bedrijven | Functie | Begin | Einde |
|---|---|---|---|
| NEXIMMUNE, INC. | Director/Board Member | 01-01-2017 | - |
| Independent Dir/Board Member | 01-01-2017 | - |
Loopbaan van Paul D'Angio
Eerdere bekende functies van Paul D'Angio
| Bedrijven | Functie | Begin | Einde |
|---|---|---|---|
| PDS BIOTECHNOLOGY CORPORATION | Corporate Officer/Principal | 01-03-2019 | 01-06-2020 |
Edge Therapeutics, Inc.
 Edge Therapeutics, Inc. BiotechnologyHealth Technology Edge Therapeutics, Inc. is clinical-stage biotechnology company, which engages in the discovery, development, and commercialization of novel, hospital-based therapies capable of transforming treatment paradigms in the management of acute, life-threatening neurological and other conditions. Its product candidate is the EG-1962. The company was founded on January 22, 2009 by Brian A. Leuthner, Robert Loch Macdonald and Carl J. Soranno and is headquartered in Berkeley Heights, NJ. | Corporate Officer/Principal | 01-12-2017 | 01-03-2019 |
| CELGENE | Corporate Officer/Principal | - | - |
Opleiding van Paul D'Angio
| Duquesne University of The Holy Spirit | Undergraduate Degree |
| Seton Hall University School of Law | Graduate Degree |
Statistieken
Internationaal
| Verenigde Staten | 7 |
Operationeel
| Corporate Officer/Principal | 3 |
| Director/Board Member | 1 |
| Independent Dir/Board Member | 1 |
Sectoraal
| Health Technology | 5 |
| Consumer Services | 3 |
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Verwante bedrijven
| Beursgenoteerde bedrijven | 2 |
|---|---|
| NEXIMMUNE, INC. | Health Technology |
| PDS BIOTECHNOLOGY CORPORATION | Health Technology |
| Bedrijven in privébezit | 2 |
|---|---|
Celgene Corp.
 Celgene Corp. BiotechnologyHealth Technology Celgene Corp. is an integrated global biopharmaceutical company, which engages in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases. Its primary commercial stage products include Revlimid, Pomalyst, Imnovid, Otezla, Abraxane, and Vidaza. The company was founded by David Stirling and Sol Barer in 1986 and is headquartered in Summit, NJ. | Health Technology |
Edge Therapeutics, Inc.
Edge Therapeutics, Inc. BiotechnologyHealth Technology Edge Therapeutics, Inc. is clinical-stage biotechnology company, which engages in the discovery, development, and commercialization of novel, hospital-based therapies capable of transforming treatment paradigms in the management of acute, life-threatening neurological and other conditions. Its product candidate is the EG-1962. The company was founded on January 22, 2009 by Brian A. Leuthner, Robert Loch Macdonald and Carl J. Soranno and is headquartered in Berkeley Heights, NJ. | Health Technology |
- Beurs
- Insiders
- Paul D'Angio
- Ervaring
